decemb
novel
coronaviru
name
first
report
wuhan
china
emerg
rapidli
spread
numer
countri
global
caus
current
pandem
caus
acut
infect
respiratori
tract
result
sever
diseas
lethal
current
approv
antivir
drug
treat
patient
urgent
need
specif
antivir
therapi
order
enter
cell
surfac
glycoprotein
spike
must
cleav
two
differ
site
host
cell
proteas
therefor
repres
potenti
drug
target
present
studi
investig
host
cell
proteas
activ
protein
human
airway
epitheli
cell
show
cleav
proprotein
convertas
furin
site
transmembran
serin
proteas
site
demonstr
essenti
activ
cell
antisensemedi
knockdown
express
show
replic
effici
inhibit
two
synthet
inhibitor
also
broad
rang
serin
proteas
inhibitor
aprotinin
addit
replic
also
strongli
inhibit
synthet
furin
inhibitor
combin
variou
inhibitor
produc
potent
antivir
activ
equimolar
amount
singl
serin
proteas
inhibitor
contrast
inhibit
endosom
cathepsin
affect
viru
data
demonstr
furin
essenti
activ
human
airway
cell
promis
drug
target
treatment
either
target
one
proteas
alon
combin
furin
inhibitor
therefor
approach
high
therapeut
potenti
treatment
introduct
decemb
new
coronaviru
cov
emerg
rapidli
spread
around
world
caus
pandem
never
observ
virus
viru
identifi
new
member
lineag
b
genu
betacoronaviru
also
contain
sever
acut
respiratori
syndrom
sar
cov
name
surfac
glycoprotein
hemagglutinin
ha
human
influenza
virus
et
al
moreov
pretreat
human
colon
human
airway
cell
broad
rang
inhibitor
camostat
mesyl
also
inhibit
activ
markedli
reduc
entri
well
vsv
pseudotyp
contain
protein
indic
trypsinlik
serin
proteas
crucial
entri
cell
howev
sequenc
analysi
protein
suggest
furin
may
also
involv
process
fig
coutard
et
al
wall
et
al
site
protein
contain
insert
four
amino
acid
provid
minim
furin
cleavag
site
rrar
contrast
protein
sarscov
instead
similar
sarscov
cleavag
site
possess
pair
dibas
motif
singl
kr
segment
kr
recogn
trypsinlik
serin
proteas
present
studi
demonstr
protein
activ
furin
also
show
inhibitor
proteas
strongli
suppress
viru
replic
human
airway
epitheli
cell
combin
type
inhibitor
synergist
effect
viru
reduct
result
show
approach
high
therapeut
potenti
treatment
cleavag
site
fretsubstr
furin
cleavag
site
novel
emerg
shown
possess
minim
furin
consensu
motif
sequenc
alanin
instead
basic
substrat
possess
nonbas
residu
posit
pseudomona
aeruginosa
exotoxin
shiga
toxin
rockwel
et
al
garten
test
whether
sequenc
protein
effici
cleav
furin
small
seri
fluoresc
reson
energi
transfer
fret
substrat
synthes
fig
compound
possess
amid
residu
fluorophor
posit
analog
sequenc
protein
merscov
sarscov
avian
infecti
bronchiti
viru
ibv
strain
beaudett
prepar
refer
substrat
moreov
two
fret
substrat
cleavag
site
mutat
synthes
evalu
whether
could
constitut
even
effici
cleavag
site
furin
wildtyp
fret
contain
optim
furin
recognit
site
virtu
mutat
posit
cleav
similar
effici
compar
wildtyp
sequenc
howev
substitut
posit
strongli
enhanc
cleavag
furin
expect
analog
refer
sequenc
ibv
also
process
furin
effici
data
show
rrar
motif
cleavag
site
effici
cleav
furin
vitro
spike
protein
cleav
furin
next
examin
whether
protein
cleav
endogen
furin
cell
cell
transient
transfect
pcagg
plasmid
encod
protein
ctermin
incub
absenc
presenc
potent
synthet
furin
inhibitor
cf
fig
manuscript
prepar
h
post
transfect
cell
lysat
subject
sdspage
western
blot
analysi
use
antibodi
myc
epitop
shown
fig
uncleav
precursor
subunit
detect
absenc
indic
cleav
endogen
proteas
site
cell
cleavag
effici
prevent
contrast
cleavag
prevent
trypsinlik
serin
proteas
inhibitor
aprotinin
thu
data
indic
protein
cleav
furin
site
cell
investig
cleavag
sinc
cell
express
endogen
unpublish
data
see
also
wwwproteinatlasorg
transfect
cell
cell
incub
absenc
presenc
suppress
cleavag
endogen
furin
interestingli
two
cleavag
product
approxim
kda
respect
detect
upon
coexpress
absenc
fig
like
detect
mycspecif
antibodi
cf
fig
presenc
minor
protein
band
detect
howev
amount
protein
present
transient
express
cell
similar
treat
untreat
cell
suggest
cleavag
site
caus
activ
small
amount
protein
detect
express
cell
presenc
like
due
residu
furin
activ
rather
cleavag
site
togeth
data
show
cleav
furin
data
suggest
proteas
cleav
differ
site
furin
process
site
cleav
site
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
confirm
knockdown
enzymat
activ
express
cell
treat
ppmo
remain
untreat
h
mrna
isol
analys
rtpcr
describ
previous
et
al
total
rna
analys
primer
design
amplifi
nucleotid
fulllength
pcr
product
bp
amplifi
untreat
scrambl
ppmo
treat
cell
wherea
shorter
pcr
fragment
bp
amplifi
ppmotreat
cell
fig
sequenc
reveal
truncat
lack
entir
exon
data
shown
confirm
ppmo
singl
dose
treatment
prior
infect
still
interfer
splice
h
pi
total
rna
isol
infect
cell
h
pi
amplifi
describ
sum
data
demonstr
inhibit
either
furin
strongli
inhibit
human
airway
cell
indic
proteas
critic
activ
contrast
endosom
cathepsin
dispens
involv
activ
cell
data
demonstr
replic
effici
reduc
inhibit
either
furin
activ
demonstr
proteas
crucial
activ
conclus
data
demonstr
furin
cleav
protein
essenti
viru
multicycl
replic
human
airway
cell
result
indic
furin
cleav
differ
site
furin
site
site
furin
compens
activ
henc
inhibit
either
one
critic
proteas
render
protein
unabl
effici
mediat
viru
entri
membran
fusion
therefor
furin
provid
promis
drug
target
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
proteolyt
process
cov
complex
process
requir
cleavag
two
differ
site
yet
fulli
understood
amino
acid
sequenc
cleavag
site
vari
among
cov
fig
suggest
partial
differ
proteas
may
involv
activ
sequenc
analys
protein
novel
emerg
suggest
rrar
motif
site
may
sensit
cleavag
furin
site
contain
singl
r
residu
cleav
hoffmann
et
al
present
studi
demonstr
protein
cleav
furin
furthermor
show
multicycl
replic
human
airway
cell
strongli
suppress
inhibit
furin
activ
demonstr
proteas
crucial
activ
cell
data
indic
furin
cleav
site
wherea
cleav
site
effect
process
site
furin
addit
confirm
furin
cleavag
site
likewis
strong
inhibit
replic
knockdown
activ
use
ppmo
treatment
cell
aprotinin
respect
indic
furin
compens
lack
activ
confirm
use
analog
fret
substrat
deriv
cleavag
site
protein
fig
kinet
measur
clearli
reveal
substrat
cleav
furin
fig
thu
could
experiment
demonstr
first
time
furin
activ
site
protein
ibv
strain
beaudett
contain
multibas
motif
site
substrat
site
ibv
beaudett
protein
effici
cleav
furin
fig
fig
howev
advantag
furincleav
multibas
motif
andor
site
multicycl
replic
cellular
tropism
pathogen
hcov
remain
determin
possess
furin
cleavag
motif
site
contrast
protein
sarscov
possess
singl
arginin
residu
cleavag
site
see
also
fig
cov
lack
insert
site
fig
wall
et
al
protein
merscov
contain
dibas
motif
sequenc
rxxr
site
thu
combin
proteas
inhibitor
eg
aprotinin
camostat
antivir
provid
promis
approach
block
replic
test
cell
cultur
anim
model
furthermor
consid
therapeut
strategi
treatment
summari
demonstr
furin
essenti
activ
cdna
encod
spike
protein
isol
genbank
access
number
codonoptim
sequenc
avail
upon
request
termin
synthes
eurofin
subclon
pcagg
express
plasmid
use
xhoi
nhei
restrict
site
express
plasmid
encod
cdna
human
describ
previous
et
al
cleavag
site
subunit
indic
black
colour
arrow
respect
immunochem
detect
recombin
express
ctermin
fuse
peptid
studi
b
align
amino
acid
sequenc
cleavag
site
protein
differ
human
coronavirus
hcov
avian
infecti
bronchiti
viru
ibv
strain
beaudett
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
cotransfect
either
empti
vector
cell
incub
absenc
presenc
aprotinin
furin
inhibitor
h
cell
lysat
subject
sdspage
western
blot
analysi
use
antibodi
ctermin
myctag
lane
splice
togeth
one
immunoblot
one
experi
treat
cell
inocul
describ
incub
absenc
ppmo
h
lane
total
rna
isol
analys
rtpcr
use
primer
design
amplifi
nt
fulllength
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
inhibitor
aprotinin
furin
endosom
cathepsin
respect
dmso
indic
concentr
h
pi
supernat
collect
viru
replic
determin
tcid
titrat
indic
time
point
data
mean
valu
sd
two
four
independ
experi
b
effect
inhibitor
treatment
cell
viabil
cell
treat
indic
proteas
inhibitor
h
untreat
cell
wo
dmso
treat
cell
use
control
cell
viabil
untreat
cell
set
result
mean
valu
sd
c
antivir
activ
combin
furin
inhibitor
human
airway
epitheli
cell
cell
inocul
moi
describ
incub
presenc
singl
proteas
inhibitor
inhibitor
combin
indic
concentr
viru
titer
supernat
determin
tcid
h
pi
data
mean
valu
sd
two
three
independ
experi
cell
treat
ppmo
h
infect
describ
incub
absenc
ppmo
wo
scrambl
without
furin
inhibitor
treatment
h
h
pi
supernat
collect
viral
titer
determin
tcid
indic
time
point
data
mean
valu
sd
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
must
cleav
two
site
trigger
fusion
viral
cellular
membran
viru
entri
order
releas
viru
genom
host
cell
cov
cleavag
believ
occur
sequenti
cleavag
site
occur
first
subsequ
cleavag
site
furin
process
site
wherea
cleav
site
proteas
compens
inhibit
either
furin
ii
iii
simultan
inhibit
proteas
iv
render
protein
fusioninact
prevent
viru
entri
inhibit
prevent
exposur
fusion
peptid
nterminu
subunit
iii
iv
inhibit
furin
cleavag
site
may
directli
interfer
viru
entri
membran
fusion
steric
blockag
conform
chang
ii
upper
scheme
may
prevent
exposur
site
ii
lower
scheme
fusioncompet
indic
blue
fusionincompet
grey
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
